1. Introduction
NAFLD, obesity, liver stiffness, adiposity, hepatic steatosis, metabolic syndrome, steatosis
OBESITY, COMPLICATIONS, NON-ALCOHOLIC FATTY LIVER DISEASE, SECONDARY, ADIPOSITY, HEPATIC STEATOSIS, METABOLIC SYNDROME, STEATOSIS, CHRONIC LIVER DISEASE
These authors contributed equally to this work.Background: Non-alcoholic fatty liver disease (NAFLD) is associated with visceral adiposity. We assessed the effectiveness of time-restricted fasting (TRF) for 16 h daily without calorie restrictions compared to standard care (SC; diet and lifestyle advice) in improving visceral adiposity and steatosis via controlled attenuation parameter (CAP). Methods: In a prospective single-blind randomized controlled trial, 32 participants with NAFLD were randomly assigned to TRF or SC for 12 weeks. The secondary endpoints were changes in liver stiffness, anthropometry, blood pressure, and other metabolic factors. Results: Twenty-eight participants completed the first arm of the study (TRF = 14, SC = 14), with 23 completing the crossover arm (TRF = 10, SC = 13). The baseline demographics were similar between the groups. Intermittent fasting caused a significant decrease in hepatic steatosis (Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a global prevalence of 29.8% [Due to the high prevalence of NAFLD and its associated liver and non-liver complications, there is a pressing need for effective treatment strategies. As NAFLD is inextricably linked to obesity and metabolic syndrome through over-nutrition [CR diets are often difficult to incorporate into the lifestyles of typical patients; therefore, adherence is often poor and inversely proportional to the severity of caloric restriction [